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Introduction
Paul Ehrlich announced the discovery of the 
eosinophil in a presentation to the Physiological 
Society of Berlin on 17 January 1879 [Ehrlich, 
1879a]. His next paper contained an extensive 
description of these cells [Ehrlich, 1879b]. 
Ehrlich identified peripheral blood eosinophils 
thanks to their capacity to be stained by eosin. He 
suggested that eosin interacted, like a ‘magic bul-
let’, with a specific eosinophil receptor. Ehrlich’s 
hypothesis of ‘chemical affinities’ in biological 
processes is epitomized in his maxim corpora non 
agunt nisi fixata, namely, a substance is not bio-
logically active unless it is bound by a receptor. 
This led him to the use of a magic bullet to treat a 
given disease. Thus, Ehrlich was not only the 
founder of modern immunology, but he was also 
a pioneer in pharmacological sciences.
Eosinophils represent approximately 1% of 
peripheral blood leukocytes in normal donors 
and their maturation and differentiation in 
the bone marrow are mainly regulated by 
interleukin (IL)-5 [Broughton et al. 2015]. IL-5, 
a cytokine that belongs to the β common- 
chain family, together with IL-3 and granulo-
cyte-macrophage colony-stimulating factor 
(GM-CSF), stimulates also the activation and 
survival of eosinophils [Yamaguchi et al. 1991] 
and, to some extent, of basophils [Bischoff et al. 
1990; Hirai et al. 1990]. IL-5 binds to a heter-
odimer receptor composed by the specific subu-
nit IL-5Rα and a common subunit βc shared 
with IL-3 and GM-CSF [Rosas et  al. 2006; 
Takatsu, 2013]. Human eosinophils express 
approximately a three-fold higher level of 
IL-5Rα compared with basophils [Kolbeck et al. 
2010]. Major sources of IL- 5 are T-helper 2 
(Th2) cells, mast cells, CD34+ progenitor cells, 
invariant natural killer (NK) T-cells, group 2 
innate lymphoid cells (ILC2s), and eosinophils 
themselves [Fallon et al. 2006; Nussbaum et al. 
2013; Phillips et  al. 2003]. ILC2s control 
not only eosinophil number but also their circa-
dian cycling through the production of IL-5 
[Nussbaum et al. 2013].
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Mepolizumab in adults with eosinophilic 
asthma
Given the critical role of IL-5 in influencing sev-
eral activities of eosinophils, this cytokine and its 
receptor attracted the attention of pharmaceutical 
industries as a possible target in the treatment of 
hypereosinophilic diseases including eosinophilic 
asthma [Varricchi et  al. 2016]. Mepolizumab 
(Nucala; GlaxoSmithKline, London, UK) was 
the first anti-IL-5 humanized monoclonal 
antibody described over 15 years ago [Zia-
Amirhosseini et al. 1999]. Mepolizumab binds to 
IL-5 with high specificity (maximal inhibitory 
concentration <1 nm) and affinity (approximately 
4.2 pM), thus preventing its binding to the α chain 
of the IL-5R complex on eosinophils and baso-
phils. A preclinical study on the pharmacology 
and safety of mepolizumab in naïve and Ascaris 
suum-sensitive Cynomolgus monkeys demonstrated 
that a single intravenous (iv) dose reduced blood 
eosinophilia for 6 weeks without affecting acute 
bronchoconstriction [Hart et al. 2001]. Two ini-
tial studies evaluated, in a randomized, double-
blind, parallel group, the effects of iv anti-IL-5 in 
a small group of mild asthmatic patients (Table 1). 
Although anti-IL-5 produced a decrease in blood 
eosinophils and partial reduction of airway and 
bone marrow eosinophils, there were no effects 
on airway hyperresponsiveness (AHR) and late 
response to inhaled allergens [Flood-Page et  al. 
2003; Leckie et  al. 2000]. Similarly, in a multi-
center study to evaluate safety and efficacy of iv 
mepolizumab in patients with moderate persistent 
asthma, the treatment produced a rapid and 
marked reduction in blood eosinophils, without 
improving lung functions and symptoms [Flood-
Page et al. 2007]. These initial studies produced 
frustrating results, and several investigators ques-
tioned the efficacy of this targeted therapy on 
asthma treatment [Flood-Page et al. 2003; Wenzel, 
Table 1. Clinical trials of mepolizumab in asthma.
Study Disease severity Dosage/delivery Outcome summary
[Menzies-Gow et al. 
2003]
Mild asthmatics 750 mg iv every 4 weeks for 3 
months
↓ Eosinophils within bronchial mucosa
[Flood-Page et al. 2003] Mild asthmatics 750 mg iv every 4 weeks for 3 
months
↓ Blood eosinophils
↓ Airway eosinophils by 50%
No effect on PEF, FEV1 and bronchial 
hyperresponsiveness
[Flood-Page et al. 2007] Moderate asthmatics 250 or 750 mg iv every 4 weeks 
for 3 months
↓ Blood and sputum eosinophils
No effect on PEF, FEV1 and AQLQ
[Haldar et al. 2009] Severe eosinophilic 
asthmatics





No effect on FEV1
[Nair et al. 2009] Prednisone-dependent 
eosinophilic asthmatics
750 mg iv every 4 weeks for 5 
months
↓ Blood and sputum eosinophils
↓ Exacerbations
Prednisone-sparing effect
[Pavord et al. 2012] Severe eosinophilic 
asthmatics
1 of 3 doses (750, 250 or 75 mg) 
iv every 4 weeks for 13 months
↓ Blood and sputum Eosinophils
↓ Exacerbations
No effect on FEV1 and AQLQ
[Ortega et al. 2014b] Severe eosinophilic 
asthmatics
MENSA STUDY






[Bel et al. 2014] Severe eosinophilic 
asthmatics
SIRIUS STUDY






[Haldar et al. 2014] Severe eosinophilic 
asthmatics
750 mg iv every 4 weeks 
Outcome after cessation
Rapid increase in blood and sputum
eosinophils followed by increased of 
asthma symptoms and exacerbations
ACQ-5, Asthma Control Questionnaire-5; AQLQ, Asthma Quality of Life Questionnaire; FEV1, forced expiratory volume in one second; iv, intrave-
nously; PEF, peak expiratory flow; sc, subcutaneously.
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2009]. In fact, no significant effects were found in 
terms of AHR, peak expiratory flow (PEF), and 
forced expiratory volume in one second (FEV1) 
despite a remarkable reduction in blood eosino-
philia [Flood-Page et al. 2003; Leckie et al. 2000].
Retrospectively, two major factors could explain 
these preliminary results. First, an incorrect selec-
tion of patients with mild or moderate asthma 
without significant eosinophilia and airway eosin-
ophilic inflammation; second, perhaps, the iv 
administration of mepolizumab. The latter obser-
vation is relevant because there is evidence that 
subcutaneous (sc) administration of human poly-
clonal immunoglobulins provides more prolonged 
serum levels of immunoglobulins compared with 
iv infusion [Spadaro et al. 2016]. The two subse-
quent studies in patients with refractory eosino-
philic asthma demonstrated some efficacy of 
mepolizumab in the control of severe asthma. 
The first one was a study on patients who had 
refractory eosinophilic asthma and a history of 
recurrent severe exacerbations [Haldar et  al. 
2009]. Patients received iv infusion of mepoli-
zumab at monthly intervals for one year. This 
treatment caused fewer severe exacerbations than 
placebo with a significant improvement in the 
Asthma Quality of Life Questionnaire (AQLQ) 
score and a decrease in blood and sputum eosino-
phils. However, also in this study there were no 
significant differences with respect to symptoms, 
FEV1 and AHR. The second study involved 
patients with sputum eosinophilia and symptoms 
despite prednisone treatment [Nair et al. 2009]. 
Although this was a study on a small group of 
patients receiving mepolizumab in 5 monthly iv 
infusion of 700 mg, the use of anti-IL-5 was asso-
ciated with a reduction in prednisone dose, reduc-
tion in eosinophil numbers and asthma control.
The DREAM trial was a large multicenter, dou-
ble-blind, placebo-controlled study recruiting a 
large number of patients with severe asthma exac-
erbations and eosinophilic inflammation. Patients 
received one of three doses of iv mepolizumab (75 
mg, 250 mg, or 750 mg) or placebo. A major aim 
of this study was to identify biomarkers less inva-
sive than induced sputum and therefore more 
applicable in clinical practice. An important find-
ing of the study was that blood eosinophil counts 
above 0.15 × 109/l were associated with drug 
effects. Another finding was that the lowest dose 
of mepolizumab had clinical and biological effi-
cacy that was comparable with higher doses on 
exacerbation rates and blood eosinophil counts, 
respectively. Mepolizumab reduced the number 
of exacerbations and blood and sputum eosino-
phils despite a small effect on FEV1, AQLQ and 
Asthma Control Questionnaire (ACQ) scores 
compared with placebo [Pavord et al. 2012].
The latter study represented an important pro-
gress in the selection of subgroups of patients 
affected by severe eosinophilic asthma with fre-
quent exacerbations. A supervised cluster analysis 
with recursive partitioning approach was applied 
to the DREAM study to identify characteristics 
able to maximize the differences among sub-
groups [Ortega et al. 2014a]. The predictors iden-
tified were blood eosinophils, airway reversibility 
and body mass index.
Two studies evaluated the effects of sc mepoli-
zumab in patients with severe asthma with more 
than two exacerbations in the previous year and a 
blood eosinophil count greater than 0.15 × 109/l 
at screening. In the SIRIUS trial, the primary out-
come was the degree of the glucocorticoid-sparing 
effect of mepolizumab (100 mg sc every 4 weeks 
for 20 weeks) [Bel et al. 2014]. Anti-IL-5 reduced 
the glucocorticoid dose and exacerbations, while 
improving the control of asthma symptoms. 
Another conclusive research was the MENSA 
trial, a multicenter, double-blind, placebo-con-
trolled study recruiting a large number of patients 
with severe eosinophilic asthma [Ortega et  al. 
2014b]. Mepolizumab (100 mg sc every 4 weeks for 
8 months) reduced asthma exacerbations, eosino-
philia and improved FEV1 and QoL. Importantly, 
a pharmaco-economic evaluation of the latter 
study showed that mepolizumab is cost effective 
in that specific context [Basu et al. 2016]. A recent 
post-hoc analysis of data from the DREAM and 
MENSA trials has shown a close relationship 
between baseline blood eosinophil count and clin-
ical efficacy of mepolizumab in patients with 
severe eosinophilic asthma and a history of exacer-
bations. The authors noted a clinically-relevant 
reduction in exacerbation frequency, defined as at 
least a 30% decrease in this endpoint, in patients 
starting from a baseline count of 150 cells/µl and 
showing better outcomes in patients with over 300 
eosinophils/µl [Ortega et  al. 2016]. Even if the 
blood eosinophilic threshold is still under discus-
sion, the use of this baseline biomarker could help 
to select patients who are likely to achieve more 
benefits in asthma control with mepolizumab. 
Based on the results of the SIRIUS and MENSA 
G Varricchi, D Bagnasco et al.
http://tar.sagepub.com 43
trials, first the United States (US) Food and Drug 
Administration, and subsequently, the European 
Medicines Agency approved mepolizumab as an 
add-on maintenance treatment for severe eosino-
philic asthma in adults. Nucala® (mepolizumab) 
is currently licensed in the US, Japan and more 
than 30 countries worldwide.
Conclusion
Several studies demonstrated that mepolizumab 
is well tolerated and efficacious in adults with 
severe eosinophilic asthma treated for up to 1 
year. A recent study examined the outcome of 
patients with severe asthma after cessation of 
mepolizumab [Haldar et al. 2014]. In fact, there 
was some concern about a possible risk of 
‘rebound’ of eosinophilic airway inflammation 
after stopping mepolizumab [Kim et al. 2004]. In 
addition, mepolizumab was associated with up-
regulation of IL-5 synthesis by Th2 cells and 
overexpression of IL-5R by eosinophils [Stein 
et al. 2008]. Cessation of mepolizumab resulted 
in a rapid increase of blood eosinophils followed 
by a gradual increase in asthma symptoms and 
exacerbations [Haldar et al. 2014]. This observa-
tion emphasizes the importance of maintaining 
suppression of eosinophilic inflammation in these 
patients. Although eosinophil deficiency appears 
to have no effects on normal health [Gleich et al. 
2013], these cells have been implicated in cancer 
rejection [Carretero et al. 2015] and several can-
cers are associated with eosinophilia [Simson 
et al. 2007]. It has been suggested that ‘targeted 
anti-eosinophilic strategies may unmask or even 
accelerate progression’ of certain tumors in 
patients with hypereosinophilic syndrome 
[Roufosse et al. 2010]. Consequently, long-term 
studies are required to evaluate the safety of tar-
geted anti-eosinophilic treatments.
In conclusion, targeted therapy with mepoli-
zumab appears to be effective in the treatment of 
severe eosinophilic asthma thereby echoing the 
concept of ‘magic bullets’ epitomized by Paul 
Ehrlich more than 130 years ago. In the current 
context, his maxim corpora non agunt nisi fixata 
can be translated as ‘mepolizumab is pharmaco-
logically active in severe eosinophilic asthma 
because it binds to IL-5’.
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